A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BMS-986209 in Healthy Participants
Latest Information Update: 07 Jan 2022
At a glance
- Drugs BMS 986209 (Primary)
- Indications Thrombosis
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 14 Dec 2021 Status changed from not yet recruiting to completed.
- 12 Nov 2019 New trial record